#United States #Elanco Animal Health #Indianapolis #R. David Hoover #Deborah Kochevar

Elanco Animal Health Board Update

Elanco Animal Health Incorporated, a pivotal player in the sphere of animal health, has recently announced essential changes to its Board of Directors. This update serves to inform stakeholders about the imminent retirements of R. David Hoover and Deborah Kochevar, who have decided not to seek re-election at the upcoming Annual Meeting of Shareholders scheduled for May 2026.

Contributions of R. David Hoover

R. David Hoover, a vital figure in Elanco’s establishment as an independent organization, has been with the Board since its inception during the company’s initial public offering (IPO) in September 2018. His leadership role as the first Chairman of the Board has been instrumental in guiding Elanco through a transformative phase that included its spin-off from Eli Lilly. Lawrence E. Kurzius, the current Chairman of the Board, commended Hoover's contributions by stating, "Dave Hoover's leadership was absolutely foundational to Elanco's success as an independent company." He noted Hoover's ability to create a sound governance framework and strategic direction that set Elanco on a path of sustainable growth.

Continuing with heartfelt sentiments, the President and CEO of Elanco, Jeff Simmons, expressed his gratitude towards Hoover, mentioning that his strategic insights were key to Elanco's positioning as a leading entity in the global animal health market. Hoover reflected on his tenure, saying, "With Elanco in a strong position and an exciting path ahead, now is the right time for me to retire."

Farewell to Deborah Kochevar

Dr. Deborah Kochevar, known for her expertise in veterinary medicine, will also be stepping down from her role. Kochevar's tenure has been marked by her leadership of Elanco's Innovation, Science, and Technology committee, where her insights considerably shaped the company’s robust pipeline of innovative animal care solutions. As Kurzius remarked, "Her critical perspectives supported our innovative strategies significantly."

Simmons added that Kochevar's emphasis on maintaining a culture of scientific excellence has played a vital role in establishing a sustained innovation momentum for the company. The leadership team recognizes her invaluable contributions as they continue to strengthen Elanco’s commitment to transforming animal care.

Future Implications for Elanco

With these strategic changes, Elanco is positioning itself for the future with a restructured Board consisting of nine directors after Hoover's and Kochevar's departures. This adjustment is seen as a pivotal moment for the company as it looks forward to innovation and long-term value creation in the animal health sector.

Elanco Animal Health has long been dedicated to innovating and providing products and services aimed at preventing and treating diseases in both farm animals and pets. With over 70 years of experience in the animal health industry, Elanco remains committed to its purpose of improving the health of animals and making a significant impact on communities globally.

The company’s vision remains clear: to enrich life through food and companionship, ensuring that their mission resonates with both their consumers and the environments they serve.

As Elanco embarks on this new chapter, it will undoubtedly continue to reflect Hoover’s influence in its governance and Kochevar's commitment to scientific innovation, as it strives to further its vision and impact in the animal health landscape.

For further details, interested parties can visit Elanco’s official website at www.elanco.com.